^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HLX43

    i
    Other names: HLX43, HLX 43, HLX-43, YL222, YL-222
    Associations
    News

    Trials

    Company:
    Fosun Pharma, MediLink
    Drug class:
    Topoisomerase I inhibitor, PD-L1-targeted antibody-drug conjugate
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors (NCT06115642)
    Phase 1
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    11/28/2023
    Primary completion :
    06/30/2025
    Completion :
    11/30/2025
    DDX5
    |
    PD-L1 expression
    |
    HLX43